Superagonistic anti-CD28 antibodies

Details Superagonistic anti-CD28 antibodies Superagonistic anti-CD28 antibodies

2011-04-07

2011-10-11

Ouspenski, Ilia (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

Reexamination Certificate

active

08034585

ABSTRACT:
The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising(a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein(i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and(ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and(b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

REFERENCES:
patent: 7585960 (2009-09-01), Hanke et al.
patent: 2003/0166860 (2003-09-01), Hunig et al.
patent: 2004/0092718 (2004-05-01), Hunig
patent: 102 30 223 (2004-01-01), None
patent: 1 600 460 (2005-11-01), None
patent: WO 98/54225 (1998-12-01), None
patent: WO 03/048194 (2003-06-01), None
patent: WO 03/078468 (2003-09-01), None
Bruggemann et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies,”J. Exp. Med.(1987), 166:1351-1361, The Rockefeller University Press.
Hamaguchi et al., “Antibody Isotype-Specific Engagement of Fcγ Receptors Regulates B Lymphocyte Depletion During CD20 Immunotherapy,”J. Exp. Med.(2006), 203(3):743-753, The Rockefeller University Press.
Isaacs et al., “A Therapeutic Human IgG4 Monoclonal Antibody that Depletes Target Cells in Humans,”Clin. Exp. Immunol.(1996), 106:427-433, Blackwell Science Ltd.
Nimmerjahn and Ravetch, “Divergent Immunoglobulin G Subclass Activity through Selective Fc Receptor Binding,”Science(2005), 310:1510-1512.
Nimmerjahn and Ravetch, “Fcγ Receptors: Old Friends and New Family Members,”Immunity(2006) 24:19-28, Elsevier Inc.
Nimmerjahn et al., “FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity,”Immunity(2005), 23:41-51, Elsevier Inc.

Affiliated with

Also associated with

Rating

Superagonistic anti-CD28 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Superagonistic anti-CD28 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Superagonistic anti-CD28 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4274485